Method of production - tablets (banks) 50 mg
Pharmacotherapeutic group - antispasmodic
Pharmacological action
m-and n-anticholinergic
spasmolytic
Ingredients - arpenal 50 mg, excipients (lactose, starch, talc, calcium stearate)
Statement
Gastrojejunal ulcer
Pain in the abdomen and pelvis
Pain localized in the upper abdomen
Pain localized to other areas of the lower abdomen
Secondary parkinsonism
Pilorospazm, not elsewhere classified
Renal colic, unspecified
Peptic ulcer unspecified localization
Other diseases of stomach and duodenum
Other and unspecified abdominal pain
Cholelithiasis
Duodenal ulcer
Gastric ulcer
The composition of the components
arpenal
lactose
calcium stearate
starch
talc
Description
White crystalline powder. Very easily soluble in water, soluble in alcohol. Aqueous solutions of hydrolyzed during storage. The structure is very close to spazmolitinu.
Pharmacodynamics
Is an antagonist of M-cholinergic receptors and a little more N-cholinergic receptors. Along with the peripheral has a moderate central holinoliticheskoe action. Also has direct spasmolytic (papaverinopodobnoe) effect on smooth muscles.
Application
Applied pilorospazme, gastric ulcer and duodenal ulcer, hepatic and renal colic. In connection with the central cholinolytic effect can be used in parkinsonism. Applied also to decrease the muscle tone in spastic paresis pyramid of different origin (in the recovery period).
Dosage regimen
Assign inside (after eating) for 0,05-0,1 g 2-4 times a day. The course of treatment an average of 3-4 weeks.
Side effects
In case of overdose can appear dizziness, headache, feeling of intoxication (in conjunction with central action), dry mouth (due to peripheral cholinolytic action), breach of accommodation. By providing an irritating effect on the gastric mucosa, spazmolitin may cause dyspeptic symptoms. The feeling of intoxication and dizziness can prevent or reduce the appointment of caffeine (0,1-0,2 g kofeinbenzoata sodium inward or 1 ml of 20% solution under the skin).
Contraindications
Glaucoma.
Pharmacotherapeutic group - antispasmodic
Pharmacological action
m-and n-anticholinergic
spasmolytic
Ingredients - arpenal 50 mg, excipients (lactose, starch, talc, calcium stearate)
Statement
Gastrojejunal ulcer
Pain in the abdomen and pelvis
Pain localized in the upper abdomen
Pain localized to other areas of the lower abdomen
Secondary parkinsonism
Pilorospazm, not elsewhere classified
Renal colic, unspecified
Peptic ulcer unspecified localization
Other diseases of stomach and duodenum
Other and unspecified abdominal pain
Cholelithiasis
Duodenal ulcer
Gastric ulcer
The composition of the components
arpenal
lactose
calcium stearate
starch
talc
Description
White crystalline powder. Very easily soluble in water, soluble in alcohol. Aqueous solutions of hydrolyzed during storage. The structure is very close to spazmolitinu.
Pharmacodynamics
Is an antagonist of M-cholinergic receptors and a little more N-cholinergic receptors. Along with the peripheral has a moderate central holinoliticheskoe action. Also has direct spasmolytic (papaverinopodobnoe) effect on smooth muscles.
Application
Applied pilorospazme, gastric ulcer and duodenal ulcer, hepatic and renal colic. In connection with the central cholinolytic effect can be used in parkinsonism. Applied also to decrease the muscle tone in spastic paresis pyramid of different origin (in the recovery period).
Dosage regimen
Assign inside (after eating) for 0,05-0,1 g 2-4 times a day. The course of treatment an average of 3-4 weeks.
Side effects
In case of overdose can appear dizziness, headache, feeling of intoxication (in conjunction with central action), dry mouth (due to peripheral cholinolytic action), breach of accommodation. By providing an irritating effect on the gastric mucosa, spazmolitin may cause dyspeptic symptoms. The feeling of intoxication and dizziness can prevent or reduce the appointment of caffeine (0,1-0,2 g kofeinbenzoata sodium inward or 1 ml of 20% solution under the skin).
Contraindications
Glaucoma.
No comments:
Post a Comment